Agoracom Blog Home

Posts Tagged ‘investment’

Else $BABY.ca $BABYF Signs Agreement to Expand into 159 Vitamin Cottage Stores Across 20 States $VERY.ca $MEAT.ca $EATS.ca $VEGN.ca

Posted by AGORACOM-JC at 8:50 AM on Wednesday, April 14th, 2021
http://blog.agoracom.com/wp-content/uploads/2020/03/else-square-150x150.png
  • Announced that it will expand distribution of it Plant-Based Complete Nutrition for Toddlers into 159 Natural Grocers by Vitamin Cottage stores across 20 states as of May 2021

VANCOUVER, BC , April 14, 2021 – ELSE NUTRITION HOLDINGS INC. (TSXV: BABY.V) (OTCQX: BABYF) (FSE: 0YL.F) (“Else” or the “Company”) the Plant-Based baby, toddler and children nutrition company , announces that it will expand distribution of it Plant-Based Complete Nutrition for Toddlers into 159 Natural Grocers by Vitamin Cottage stores across 20 states as of May 2021.

“Launching at Natural Grocers by Vitamin Cottage drives significant and strategic distribution for the brand. We are particularly excited by the alignment between this retailer and with our brand, both focusing on helping people through sustainable, organic nutrition solutions, said Hamutal Yitzhak , Else CEO and Co-Founder. “We are eager to bring real, organic and whole food-based, clean label solutions to families in this region,” she added.

About Natural Grocers by Vitamin Cottage

Natural Grocers by Vitamin Cottage, Inc. (NYSE: NGVC) is one of the leading natural food grocers in the US, with 159 stores in 20 states west of the Mississippi river. Founded in 1955, Natural Grocers is an expanding specialty retailer of natural and organic groceries, body care products, and dietary supplements. The products sold by Natural Grocers must meet strict quality guidelines and may not contain artificial colors, flavors, preservatives or sweeteners, or partially hydrogenated or hydrogenated oils. The Company sells only USDA certified organic produce and exclusively pasture-raised, non-confinement dairy products, and free-range eggs. Natural Grocers’ flexible smaller-store format allows it to offer affordable prices in a shopper-friendly, safe, and convenient retail environment. The Company also provides extensive free science-based Nutrition Education programs to help customers make informed health and nutrition choices.

About Else Nutrition Holdings Inc.

Else Nutrition GH Ltd. is an Israel -based food and nutrition company focused on developing innovative, clean and plant-based food and nutrition products for infants, toddlers, children, and adults. Its revolutionary, plant-based, non-soy, formula is a clean-ingredient alternative to dairy-based formula. Else Nutrition (formerly INDI) won the “2017 Best Health and Diet Solutions” award at the Global Food Innovation Summit in Milan . Else Plant-Based Complete Nutrition for Toddlers was recently ranked as the #1 Top seller in the baby and toddler formula category on Amazon. The holding company, Else Nutrition Holdings Inc., is a publicly traded company, listed as TSX Venture Exchange under the trading symbol BABY and is quoted on the US OTC Markets QX board under the trading symbol BABYF and on the Frankfurt Exchange under the symbol 0YL. Else’s Executives includes leaders hailing from leading infant nutrition companies. Many of Else advisory board  members had past executive roles in companies such as Mead Johnson, Abbott Nutrition, Plum Organics and leading infant nutrition Societies,  and some of them currently serve in different roles in leading medical centers and academic institutes such as Boston Children’s Hospital, Pediatrics at Harvard Medical School , USA , Tel Aviv University , Schneider Children’s Medical Center of Israel , Rambam Medical Center and Technion, Israel and University Hospital Brussels, Belgium .

TSX Venture Exchange

Neither the TSX Venture Exchange nor its regulation services provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Caution Regarding Forward-Looking Statements

This press release contains statements that may constitute “forward-looking statements” within the meaning of applicable securities legislation. Forward-looking statements are typically identified by words such as “will” or similar expressions. Forward-looking statements in this press release include statements with respect to the anticipated dates for filing the Company’s financial disclosure documents.  Such forward-looking statements reflect current estimates, beliefs and assumptions, which are based on management’s perception of current conditions and expected future developments, as well as other factors management believes are appropriate in the circumstances. No assurance can be given that the foregoing will prove to be correct. Forward-looking statements made in this press release assume, among others, the expectation that there will be no interruptions or supply chain failures as a result of COVID 19 and that the manufacturing, broker and supply logistic agreement with the Company do not terminate.  Actual results may differ from the estimates, beliefs and assumptions expressed or implied in the forward-looking statements.  Readers are cautioned not to place undue reliance on any forward-looking statements, which reflect management’s expectations only as of the date of this press release. The Company disclaims any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

Valeo Pharma $VPH $VPHIF Announces $4.0 Million Non-Brokered Private Placement of Non-Convertible Debentures $HLS.ca $MDP.ca $GUD.ca $RX.ca

Posted by AGORACOM-JC at 8:44 AM on Wednesday, April 14th, 2021
  • Announced today a non-brokered private placement of up to 4,000 unsecured non-convertible debentures units (the “Debenture Units”) at a price of $1,000 per Debenture Unit for maximum gross proceeds of $4,000,000
  • Valeo insiders participate for $2.6 million

MONTREAL , April 14, 2021 – Valeo Pharma Inc . (CSE: VPH) (OTCQB: VPHIF) (FSE: VP2) (“Valeo” or the “Company”), a Canadian pharmaceutical company, announced today a non-brokered private placement of up to 4,000 unsecured non-convertible debentures units (the “Debenture Units”) at a price of $1,000 per Debenture Unit for maximum gross proceeds of $4,000,000 (the “Offering”).

Each Debenture Unit will consist of one (1) unsecured non-convertible debenture of the Company in the principal amount of $1,000 (each, a “Debenture”) and 200 Class “A” share purchase warrants (each, a “Warrant”). Each Warrant will entitle the holder thereof to purchase one Class “A” Share of the Company (each, a “Share”) at an exercise price of $1.60 at any time up to 24 months following the closing date of the Offering (the “Closing Date”). The Debentures will mature at the latest 9 months after the closing and will bear interest at a rate of 8% per annum from the date of issue, payable in cash, semi-annually in arrears.

“We are appreciative of the continued support from insiders and investors close to the Company  in this placement”, said Steve Saviuk , Valeo’s Chief Executive Officer. “This financing will strengthen our balance sheet at a time of three important product launches for Valeo, Enerzair® Breezhaler®, Atectura® Breezhaler® and Redesca™. Commercialized through two distinct sales forces, these products are key drivers to our growth over the coming years”.

The net proceeds of the Offering will be used for working capital and general corporate purposes.

Closing of the Private Placement is expected to occur on or about April 23, 2021 and is subject to regulatory approval including that of the CSE. The Company may pay finder’s fees on the non-insider portion of the Private Placement, in compliance with applicable securities laws. All securities issued in connection with the Private Placement will be subject to a statutory hold period of four months plus one day from the date of issuance in accordance with applicable securities legislation.

The issuance of Convertible Debentures to the insiders will be considered related party transactions within the meaning of Multilateral Instrument 61-101 (“MI 61-101”). The Company intends to rely on the exemptions from the requirements of MI 61-101 in respect of any Insider Participation.

This press release is not an offer to sell or the solicitation of an offer to buy the securities in the United States or in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to qualification or registration under the securities laws of such jurisdiction. The securities being offered have not been, nor will they be, registered under the United States Securities Act of 1933, as amended, and such securities may not be offered or sold within the United States or to, or for the account or benefit of, U.S. persons absent registration or an applicable exemption from U.S. registration requirements and applicable U.S. state securities laws.

About Valeo Pharma

Valeo Pharma is a Canadian pharmaceutical company dedicated to the commercialization of innovative prescription products in Canada with a focus on Respiratory Diseases, Neurology, Oncology and Hospital Specialty Products. Headquartered in Kirkland, Quebec Valeo Pharma has all the required capabilities and the full infrastructure to register and properly manage its growing product portfolio through all stages of commercialization. For more information, please visit www.valeopharma.com and follow us on LinkedIn and Twitter .

Forward Looking Statements

This press release contains forward-looking statements about Valeo’s objectives, strategies and businesses that involve risks and uncertainties. These statements are “forward-looking” because they are based on our current expectations about the markets we operate in and on various estimates and assumptions. Actual events or results may differ materially from those anticipated in these forward-looking statements if known or unknown risks affect our business, or if our estimates or assumptions turn out to be inaccurate.

NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATIONS SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE. 

Else $BABY.ca $BABYF to launch product rollout to “Big Y” stores in April $VERY.ca $MEAT.ca $EATS.ca $VEGN.ca

Posted by AGORACOM-JC at 8:03 AM on Wednesday, April 7th, 2021
http://blog.agoracom.com/wp-content/uploads/2020/03/else-square-150x150.png
  • Announced that it will begin its Northeast rollout by mid April 2021 , through “Big Y” World Class Markets, out of Springfield Massachusetts
  • Else’s Plant-Based Nutrition for Toddlers will be available for purchase in all 71 Big Y grocery stores.

VANCOUVER, BC , April 7, 2021 – ELSE NUTRITION HOLDINGS INC. (TSXV: BABY) (OTCQX: BABYF) (FSE: 0YL) (“Else” or the “Company”) the Plant-Based baby, toddler and children nutrition company , announces that it will begin its Northeast rollout by mid April 2021 , through “Big Y” World Class Markets, out of Springfield Massachusetts . Else’s Plant-Based Nutrition for Toddlers will be available for purchase in all 71 Big Y grocery stores.

“Launching with Big Y represents another exciting milestone for Else,” said Hamutal Yitzhak , Else CEO and Co-Founder. “The northeast population size is paramount to the growth of our brand. Big Y’s large-format shelves and health-minded shoppers represent an opening into the progressive New England customer-base. We are eager to bring real, whole food-based, clean label solutions to families in this region,” she added.

About Big Y

Big Y is one of the largest independently owned supermarket chains in New England , and it employs over 12,000 people. In 2020 Big Y was the 210th-largest private company in the United States , according to that year’s Forbes magazine “500 Largest Private Companies” list. As of October 2020 , Big Y operates 71 supermarkets in Massachusetts and Connecticut ; [1] [3] many of which are located in the metropolitan areas of Springfield , Worcester , Greater Boston , and Hartford . In addition to its traditional supermarkets, Big Y owns and operates two specialty markets: Table & Vine, a large specialty liquor and wine store in West Springfield ; and the Fresh Acres Market, a concept mixing an open-air-style farmers’ market with upscale food choices, in Springfield . Big Y also operated two standalone pharmacies in Springfield and Wilbraham before eventually folding them into the pharmacies located in its nearby stores.

VIDEO – ImagineAR $IP.ca $IPNFF “March Madness” Ends With 13 Announcements And 23 Deals / Selections By The Biggest Names In Sports, Media and Entertainment For Its Augmented Reality Engagement Technology $DBO.ca $YDX.ca $SEV.ca $NTAR.ca

Posted by AGORACOM-JC at 2:15 PM on Tuesday, April 6th, 2021
http://www.smallcapepicenter.com/imagine%20ar%20squre.jpg

NCAA March Madness concluded last night with Baylor beating Gonzaga …. but the small cap augmented reality March Madness ended last week with ImagineAR making 13 announcements leading to 23 deals or selections by the biggest name in sports, media and entertainment including:

  • Minnesota Vikings / Philadelphia Phillies / St. Louis Blues
  • Rogers Sports & Media ($14B revenue / $30B Market Cap)
  • Sinclair Broadcast Group ($6B revenue / $2B Market Cap
  • First Tube Media / Grubhub / Megahan Thee Stallion
  • Global Sports Initiative 3 Year / $380,000
  • Brazilian Soccer Club Atlectio Mineiro
  • …. and much more including the company’s rapidly evolving NFT initiative (Oasis Digital Studios) with Liquid Avatar Technologies

As the name implies, ImagineAR (IP:CSE / IPNFF:OTCQB) is an Augmented Reality Company … but they’re not just any AR company.  Imagine enables businesses to create their own mobile phone AR campaigns with no programming or technology experience.  

Why is that important?  Ask Apple CEO Tim Cook who stated

“AR Will play an important role in how we use technology in the future – and promises to be as influential in our society as the smart phone”  

For those of you that are just discovering Augmented Reality, “AR” is essentially a technology that lays digital images and graphics over the real world, typically by looking through your cell phone or special glasses.  If you think it sounds like a gimmick, it isn’t.  AR will create an entire new revenue stream for businesses, organizations and sports teams that will boggle the mind in the next 3 years.

ImagineAR provides small cap investors with an opportunity to participate in the growth of this mega market in the making …. and IP delivered a record Q1 to prove it, including being selected by First Tube Media to bring its AR to livestream programs.  On it’s face, you can’t blame investors for thinking “ok, cool little initiative” …. until you discover that ImagineAR premiered its Web AR capabilities at GrubHub Sound Bites, an interactive concert featuring none other than 3-time Grammy Winner and Global Superstar Megan Thee Stallion on March 26th.  How did they perform?  World Renown Billboard Magazine reported: 

Within the first 48 hours following the livestream, over 10 million viewers have engaged with the content while driving over 160k interactions from the QR’s scan engagement.

Yep .. they blew their numbers out of the water.

And then there’s the Company’s partnership with Liquid Avatar Technologies (LQID:CSE) to bring AR Enhanced NFTs to market through Oasis Digital Studios, which on its face you couldn’t blame investors for once again thinking “ok cool little initiative” … until you discover:

  • On March 15th they teamed up with McCartney Media Inc to support the development of AR Enhanced NFT’s for the entertainment and lifestyle sectors, becoming a major player in the NFT space.
  • Just two weeks later, LQID, IP and McCartney Multimedia announced that renowned photographer, artist and former music executive, May Pang is bringing her personal and exclusive collection of John Lennon’s Lost Weekend photographs featuring her intimate 18 months with the rock ‘n’ roll icon to the Non-Fungible Token (NFT) collector market through Oasis Digital Studios.

In two weeks Oasis has moved from an exciting initiative to on the verge of making NFT history.

Watch this incredible interview with CEO Alen Paul Silverrstieen to discover how fast ImagineAR is moving and why its March Madness is just the beginning of what’s to come in 2021.   

AGORACOM Small Cap 60: ImagineAR $IP.ca $IPNFF Inked 2nd 3-year $380K+Rev Share Deal with Global Sports Initiatives $DBO.ca $YDX.ca $SEV.ca $NTAR.ca

Posted by AGORACOM-JC at 12:05 PM on Tuesday, April 6th, 2021
http://www.smallcapepicenter.com/imagine%20ar%20squre.jpg

Valeo Pharma $VPH $VPHIF Completes Negotiations with Pan-Canadian Pharmaceutical Alliance for Redesca® and Redesca HP® $HLS.ca $MDP.ca $GUD.ca $RX.ca

Posted by AGORACOM-JC at 8:12 AM on Tuesday, April 6th, 2021
  • Completed its negotiations and entered into a letter of intent (“LOI”) with the pan-Canadian Pharmaceutical Alliance (pCPA) regarding Redesca® and Redesca HP®, its low molecular weight heparin (“LMWH”) biosimilar, for the prevention and treatment of thromboembolic disorders.

MONTREAL , April 6, 2021 – Valeo Pharma Inc . (CSE: VPH) (OTCQB: VPHIF) (FSE: VP2) (” Valeo ” or the ” Company “), a Canadian specialty pharmaceutical company, today announced that it has completed its negotiations and entered into a letter of intent (“LOI”) with the pan-Canadian Pharmaceutical Alliance (pCPA) regarding Redesca® and Redesca HP®, its low molecular weight heparin (“LMWH”) biosimilar, for the prevention and treatment of thromboembolic disorders.

“The successful conclusion of negotiations with pCPA is a significant milestone delivered for the Redesca® commercialization program. We can now exchange with the provincial, territories and federal instances to ensure coverage under publicly funded drug plans in Canada “, said Steve Saviuk , Valeo’s CEO.” While most prescriptions of LMWHs are initiated in the hospital, retail pharmacies play an important role in providing continued treatment to patients when they are discharged from hospital. Coverage by publicly funded drug plans are therefor a key component in making treatment available to Canadians”.

Commenting on the pCPA LOI, Frederic Fasano , Valeo’s President and Chief Operating Officer said; “We are particularly pleased to make Redesca ® available soon for Canadian patients and also for hospitals. The team at Valeo have worked tirelessly to ensure a robust supply of Redesca ® especially in the current pandemic conditions where patients suffering from SARS-CoV-2 are undergoing severe coagulopathy with various thromboembolic complications. LMWHs, like Redesca ® are key to prevent and treat those severe COVID-19 related thrombotic events.”

Established in August 2010 , the pan-Canadian Pharmaceutical Alliance (pCPA) conducts joint provincial/territorial/federal negotiations for brand name and generic drugs in Canada to achieve greater value for publicly funded drug programs and patients through the use of the combined negotiating power of participating jurisdictions.

About Redesca®, Redesca HP®

Redesca® is a low molecular weight heparin biosimilar. LMWHs are injectable anticoagulant drugs used primarily to treat and prevent deep vein thrombosis and pulmonary embolism. Redesca® has more than 8 years of proven in-market safety internationally and more than 150 million patient days treated in Europe alone.

About Valeo Pharma

Valeo Pharma is a Canadian pharmaceutical company dedicated to the commercialization of innovative prescription products in Canada with a focus on Respiratory Diseases, Neurodegenerative Diseases, Oncology and Hospital Specialty Products. Headquartered in Kirkland, Quebec Valeo Pharma has all the required capabilities and the full infrastructure to register and properly manage its growing product portfolio through all stages of commercialization. For more information, please visit www.valeopharma.com and follow us on LinkedIn and Twitter .

Read More: https://agoracom.com/ir/ValeoPharma/forums/discussion/topics/758564-valeo-pharma-completes-negotiations-with-pan-canadian-pharmaceutical-alliance-for-redesca-and-redesca-hp/messages/2310948#message

AGORACOM Small Cap 60: Wildly Successful Partnership With First Tube Media Puts ImagineAR On The Map $DBO.ca $YDX.ca $SEV.ca $NTAR.ca

Posted by AGORACOM-JC at 1:01 PM on Thursday, April 1st, 2021
http://www.smallcapepicenter.com/imagine%20ar%20squre.jpg

AGORACOM Small Cap 60: What Gives Valeo Pharma A Competitive Advantage In The $700M CAD / Year Asthma Market? $HLS.ca $MDP.ca $GUD.ca $RX.ca

Posted by AGORACOM-JC at 12:02 PM on Thursday, April 1st, 2021

ImagineAR $IP.ca $IPNFF Selected by 13 Sports Organizations and Media Broadcasters on Hype Sports Innovation Draft Day $DBO.ca $YDX.ca $SEV.ca $NTAR.ca

Posted by AGORACOM-JC at 7:54 AM on Thursday, April 1st, 2021
http://www.smallcapepicenter.com/imagine%20ar%20squre.jpg

ImagineAR Selections Include Sinclair Broadcast Group, Rogers Sports & Media, Vegas Knights, Philadelphia Phillies, Minnesota Vikings

  • Announced that thirteen different Sports Teams, Federations and Media Broadcasters selected ImagineAR during the Hype Sports Innovation Draft Day on March 31, 2021
  • HYPE Sports Innovation has built the largest global ecosystem in sports innovation.
  • With over 40,000 members, including retail brands, athletic clubs, federations and academia together with over 11,000 startups, HYPE has an unrivalled capacity for outreach to global partners across all sectors in this highly diverse field.

VANCOUVER, BC and ERIE, Pa. , April 1, 2021 – Imagine AR Inc. (CSE: IP) (OTCQB: IPNFF) (“ImagineAR” or “Company”) an Augmented Reality Company that enables sports teams, businesses and enterprises to instantly create their own AR mobile campaigns, is pleased to announce that thirteen different Sports Teams, Federations and Media Broadcasters selected ImagineAR during the Hype Sports Innovation Draft Day on March 31, 2021 .

“Today’s Hype Sports Innovation Draft Day was a historic event for the stakeholders of ImagineAR that goes beyond the selection of 13 rights holders representing a worldwide list of sports federations, teams, and media broadcast groups,” said Neal Bendesky , ImagineAR’s VP of Sports. “We are appreciative to Ryan McCumber and the Hype team for offering this unique opportunity for emerging start-ups to help these partners to adjust and innovate after the pandemic.  Our augmented reality platform is an effective tool to assist the sports, music, retail and entertainment industries imagine and adapt to blaze a new trail for their business models.  Thanks to Hype, we can now grow our brand and activate AR solutions for worldwide clients including:”

NFL: Minnesota Vikings
MLB: Philadelphia Phillies
NHL: St. Louis Blues , Vegas Golden Knights
World Governing Body of Cricket: International Cricket Council (ICC)
World Governing Body of Football: Deutscher Fußball-Bund (DFB)
Bundesliga: 1. FC Koln
Leading provider of Local Sports & News ( USA ): Sinclair Broadcast Group
Leading provider Mass Media & Sports Properties ( Canada ): Rogers Sports & Media
Serie A (Top flight of Italian Football): Bologna FC
Uruguayan Primera Division: C.FdeF
MLS & USL: Inter Miami
Categoria Primera A: Atletico Nacional

HYPE Sports Innovation has built the largest global ecosystem in sports innovation. With over 40,000 members, including retail brands, athletic clubs, federations and academia together with over 11,000 startups, HYPE has an unrivalled capacity for outreach to global partners across all sectors in this highly diverse field.

GrubHub WebAR Live Streaming Concert with Megan Thee Stallion
(Billboard March 29, 2021 )

As per the Billboard Article published on March 29, 2021 , ‘ Megan Thee Stallion , Noah Cyrus and King Princess Take Over GrubHub Sound Bites Interactive Concert’ , Noah Cyrus , King Princess and Megan Thee Stallion came together for GrubHub Sound Bites’s first-ever immersive AR livestream concert. The free event, which virtually took place on March 26 , honored Women’s History Month and World Central Kitchen.

As part of the ImagineAR experience, fans were encouraged to scan customized QR codes that appeared throughout the show to receive special discounts and perks. Those included a chance to win a meet-and-greet with each artist, seeing behind-the-scenes footage, winning a $5 perk to place orders and chances to win a GrubHub gift card.

Within the first 48 hours following the livestream, over 10 million viewers have engaged with the content while driving over 160k interactions from the QR’s scan engagement.

“This was ImagineAR’s first successful WebAR event for First Tube Media and probably the biggest music live streaming WebAR event in history” according to Alen Paul Silverrstieen, CEO of ImagineAR.

ImagineAR Issues Stock Options to Directors and Officers

Imagine AR announces that on April 1, 2021 the Company granted 1,500,000 stock options to directors and officers of the Company.  These stock options are granted in accordance with the terms of the stock option plan of ImagineAR Inc.  The options will vest 50% on the date of grant with the remainder vesting in 90 days and each option entitles the holder thereof to purchase one (1) common share of ImagineAR Inc. at a price of $0.41 per common share for a period of three (3) year.

Valeo Pharma $VPH $VPHIF Reports its First Quarter 2021 Results and Highlights $HLS.ca $MDP.ca $GUD.ca $RX.ca

Posted by AGORACOM-JC at 6:40 PM on Wednesday, March 31st, 2021
  • Valeo secured the Canadian rights to Enerzair® Breezhaler® and Atectura® Breezhaler®, two new innovative Asthma therapies
  • Q1-21 net revenues of $1.9 million , up 11 % vs Q1-20
  • Frederic Fasano appointed as President and Chief Operating Officer
  • Redesca® and Redesca HP® receive Health Canada approval, launching in Q3
  • Hesperco™ capsules at the core of a Montreal Heart Institute’s COVID-19 study

MONTREAL , March 31, 2021 – Valeo Pharma Inc . (CSE: VPH) (OTCQB: VPHIF) (FSE: VP2) (” Valeo ” or the ” Company “), a Canadian pharmaceutical company, today reported its financial results for the first quarter ended January 31, 2021 .

“Our first quarter has laid the foundation for a transformational year for Valeo. The commercialization agreement with Novartis Canada positions  Valeo as one of the leading Canadian companies in respirology .  We are excited about the opportunity to enter the growing asthma market with two innovative drugs, Enerzair® Breezhaler® and Atectura® Breezhaler®.  The Canadian asthma market exceeds $700 million annually 1 and is expected to growth at 2-3% per year over the next ten years. We expect combined peak sales of these two new drugs to exceed $100 million annually.”, said Steve Saviuk , Valeo’s CEO. “With the coming launch of Redesca, our low-molecular-weight-heparin biosimilar, and the Montreal Institute of Cardiology’s ongoing Covid-19 clinical trial involving Hesperco capsules, 2021 marks a turning point in Valeo’s history”.

Commenting on the first quarter 2021 results, Luc Mainville , Senior Vice-President and Chief Financial Officer said, “Our net revenues for the quarter continued to grow and reflected the addition of several products during the latter part of our 2020 fiscal year. Our first quarter results were impacted by calendar year-end slowdown of the pharma sector as well as increase in operating expenses to support our growth initiatives. Sales & Marketing expenses increased due to the addition of Redesca’s national key account manager team. Our General & Administrative expenses also increased during the quarter as a result of the addition to the Head Office personnel and increased marketing related expenses. We expect additional investments to be made in 2021 as we prepare ourselves to support the Canadian commercialization of Enerzair® Breezhaler® and Atectura® Breezhaler® already approved by Health Canada and available for sale. We anticipate strong revenue growth in the second quarter of fiscal 2021 and accelerated growth in the coming quarters as a result of these product additions which will derive incremental margins and drive our profitability going forward.

References:

  1. IQVIA CDH June 2020

First Quarter 2021 Financial Results and Highlights

  • Net revenues were $1.9 million for the quarter ended January 31, 2021 compared to $1.7 million for the quarter ended January 31, 2020 . The increase over the previous comparable period is mainly due to the Onstryv revenue growth and the launch of new products such as Ametop, Yondelis and the launch of Sodium Ethacrynate in the U.S. ;
  • Net loss of $1.7 million for the quarter ended January 31, 2021 compared to $1.1 million for the quarter ended January 31, 2020 . The increase in net loss is a result of the increase in Sales & Marketing and General & Administrative expenses required to position Valeo for solid revenue growth in 2021; and
  • Adjusted EBITDA loss of $1.1 million for the quarter ended January 31, 2021 compared to $0.9 million for the quarter ended January 31, 2020 .

First Quarter 2021 Business and Product Highlights

  • In January 2021 , the Company received notice of a positive recommendation by Quebec’s Institut national d’excellence en santé et en services sociaux (“INESSS”) to the Health Minister for the inclusion of Redesca® and Redesca® HP, on the list of medications covered by the Régie de l’assurance maladie du Québec (RAMQ);
  • In January 2021 , the Company appointed Mr. Frederic Fasano to the newly created position of President and Chief Operating Officer. Mr. Fasano is a seasoned Canadian and international pharma executive having lead pharmaceutical organizations in Europe and Canada. His addition augments Valeo’s senior leadership team and support expansion of Valeo’s commercial activities;
  • In December 2020 , the Company announced that its shares were eligible for electronic clearing and settlement in the U.S. through the Depository Trust Company (“DTC”);
  • In December 2020 , the Company received a Notice of Compliance from Health Canada for its Redesca and Redesca HP low molecular weight heparin (“LMWH”) biosimilars; and
  • In November 2020 , the Company received a Notice of Compliance from Health Canada granting market authorization for Amikacin and commenced shipments of Ethacrynate Sodium in the U.S. market.

Subsequent Events

  • In March 2021 , the Company entered into a Commercial and Supply Agreement with Novartis Pharmaceuticals Canada Inc. for the Canadian commercialization by Valeo of two innovative asthma therapies, Enerzair ® Breezhaler ® (indacaterol (as acetate), glycopyrronium (as bromide) and mometasone furoate) and Atectura ® Breezhaler ® (indacaterol (as acetate) and mometasone furoate); and
  • In February 2021 , the Company announced that Hesperco™ capsules, approved by Health Canada for immune support, will be at the core of the Montreal Heart Institute’s (“MHI”) clinical trial, “The Hesperidin Coronavirus Study”;

Q1 2021 Webcast and Conference Call

Valeo will host a conference call to discuss the first quarter 2021 results and highlights on Thursday April 1, 2021 at 8.30am (EST) . The telephone numbers to access the conference call are 1-888-231-8191 and 647-427-7450. An audio replay of the call will be available. The numbers to access the audio replay are 1-855-859-2056 and 416-849-0833 using the following access code (5555964).

A live audio webcast of the conference call will be available via:

https://produceredition.webcasts.com/starthere.jsp?ei=1444812&tp_key=929d96e070

Financial Statements and MD&A

Valeo Pharma’s financial statements and Management’s Discussion and Analysis for the three-month ended January 31, 2021 are available on SEDAR at www.sedar.com

About Valeo Pharma

Valeo Pharma is a Canadian pharmaceutical company dedicated to the commercialization of innovative prescription products in Canada with a focus on Respiratory Diseases, Neurodegenerative Diseases, Oncology and Hospital Specialty Products. Headquartered in Kirkland, Quebec Valeo Pharma has all the required capabilities and the full infrastructure to register and properly manage its growing product portfolio through all stages of commercialization. For more information, please visit www.valeopharma.com and follow us on LinkedIn and Twitter .

Forward Looking Statements

This press release contains forward-looking statements about Valeo’s objectives, strategies and businesses that involve risks and uncertainties. These statements are “forward-looking” because they are based on our current expectations about the markets we operate in and on various estimates and assumptions. Actual events or results may differ materially from those anticipated in these forward-looking statements if known or unknown risks affect our business, or if our estimates or assumptions turn out to be inaccurate. The Company is not making any express or implied claims that its product has the ability to eliminate, cure or contain the Covid-19 (or SARS-2 Coronavirus) at this time.

NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATIONS SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.